Valsartan Restores Sarcoplasmic Reticulum Function with No Appreciable Effect on Resting Cardiac Function in Pacing-Induced Heart Failure

Circulation

Volumn 109, Issue 7, 2004, Pages 911-919

  Okuda, Shinichi ^a   Yano, Masafumi ^a   Doi, Masahiro ^a   Oda, Tetsuro ^a   Tokuhisa, Takahiro ^a   Kohno, Masateru ^a   Kobayashi, Shigeki ^a   Yamamoto, Takeshi ^a   Ohkusa, Tomoko ^a   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcium; Heart failure; Ion channels; Sarcoplasmic reticulum

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOBUTAMINE; FK 506 BINDING PROTEIN; NORADRENALIN; RYANODINE; RYANODINE RECEPTOR; TACROLIMUS; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; DOG; DOSE CALCULATION; ENZYME PHOSPHORYLATION; HEART FAILURE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MUSCLE; HEART LEFT VENTRICLE PRESSURE; HEART VENTRICLE PACING; HEART VENTRICLE REMODELING; HEMODYNAMICS; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SARCOPLASMIC RETICULUM;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CALCIUM SIGNALING; CALCIUM-TRANSPORTING ATPASES; CARDIAC PACING, ARTIFICIAL; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOBUTAMINE; DOGS; DRUG EVALUATION, PRECLINICAL; HEART FAILURE, CONGESTIVE; MYOCARDIAL CONTRACTION; NOREPINEPHRINE; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, ADRENERGIC, BETA; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM; TACHYCARDIA, VENTRICULAR; TACROLIMUS BINDING PROTEINS; TETRAZOLES; VALINE; VENTRICULAR REMODELING;

EID: 10744228679     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000115526.92541.D2     Document Type: Article

References (21)

1. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res. 1998;37:279-289.
2. Marks AR. Ryanodine receptors/calcium release channels in heart failure and sudden cardiac death. J Mol Cell Cardiol. 2001;33:615-624.
3. 2+ leak through ryanodine receptor in heart failure. Circulation. 2000;102:2131-2136.
4. Reiken S, Gaburjakova M, Gaburjakova JJ, et al. β-Adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation. 2001;104:2843-2848.
5. Doi M, Yano M, Kobayashi S, et al. Propranolol prevents the development of heart failure by restoring FKBP12.6-mediated stabilization of ryanodine receptor. Circulation. 2002;105:1374-1379.
6. Marx SO, Reiken S, Hisamatsu Y, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-376.
7. Yano M, Kobayashi S, Kohno M, et al. FKBP12.6-mediated stabilization of calcium-release channel (ryanodine receptor) as a novel therapeutic strategy against heart failure. Circulation. 2003;107:477-484.
8. Bruckschlegel G, Holmer SR, Jandeleit K, et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250-259.
9. 1-receptor blockade. Cardiovasc Res. 1996;31:758-768.
10. 2+ release from cardiac sarcoplasmic reticulum in tachycardia-induced heart failure. Cardiovasc Res. 1999;44:146-155.
11. Kranias E, Schwarts A, Jungmann RA. Characterization of cyclic 3′:5′-AMP-dependent protein kinase in sarcoplasmic reticulum and cytosol of canine myocardium. Biochim Biophys Acta. 1982;709:28-37.
12. Abrahamsson T, Ek B, Nerme V. The β1- and β2-adrenoceptor affinity of atenolol and metoprolol. Biochem Pharmacol. 1988;37:203-208.
13. Himura Y, Felten SY, Kashiki M, et al. Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation. 1993;88:1299-1309.
14. Honda S, Takahashi M, Araki Y, et al. Pastcolimn derivatization of catecholamines with 2-cyanoacetamide for fluorimetric monitoring in high-performance liquid chromatography. J Chromatogr. 1983;274: 45-52.
15. Goldberg ML. Radioimmunoassay for adonosine 3′,5′-cyclic monophosphate and guanosine 3′,5′-cyclic monophosphate in human blood, urine, and cerebrospinal fluid. Clin Chem. 1977;23:576-580.
16. Spinale FG, de Gasparo M, Whitebread S, et al. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure, I: effects on left ventricular performance and neurohormonal system. Circulation. 1997;96: 2385-2396.
17. Lanier SM, Malik KU. Facilitation of adrenergic transmission in the canine heart by intracoronary infusion of angiotensin II: effect of prostaglandin synthesis inhibition. J Pharmacol Exp Ther. 1983;227: 676-682.
18. 2-receptor-mediated vasoconstriction in patients with congestive heart failure. Circulation. 1989;80: 1660-1667.
19. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation. 2000;101:558-569.
20. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
21. 2+ release, but normal ryanodine receptors, in canine and human heart failure. Circ Res. 2002;91:1015-1022.